Together, this graded response to FAKi priming before gemcitabine/Abraxane between TKCC05 and TKCC10 PDCLs highlights the need to identify valid biomarkers to guide combination treatment regimens in a personalized medicine approach to this highly heterogeneous disease, where the FAK activity status of patient tumors could be potentially used to identify patients who may benefit from FAKi priming before chemotherapy and recognize patients who may not respond to current clinical FAK-based targeted therapy in PC (19). The gene discussed is PTK2; the disease is pachyonychia congenita.